Idexx Laboratories Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 96.36% of US listed stocks.
With a one year PEG ratio of 613.2, Idexx Laboratories Inc is expected to have a higher PEG ratio (a measure of how expensive a stock is relative to its expected earnings growth) than 94.36% of US stocks.
Price to trailing twelve month operating cash flow for IDXX is currently 63.85, higher than 94.71% of US stocks with positive operating cash flow.
Stocks that are quantitatively similar to IDXX, based on their financial statements, market capitalization, and price volatility, are CLX, EBAY, ROK, BBY, and CVNA.
IDXX's SEC filings can be seen here. And to visit Idexx Laboratories Inc's official web site, go to www.idexx.com.
IDEXX Laboratories develops, manufactures, and distributes products and services primarily for the companion animal veterinary, livestock and poultry, water testing, and dairy markets worldwide. The company was founded in 1983 and is based in Westbrook, Maine.
IDXX Price Forecast Based on DCF Valuation
DCF Fair Value Target:
We started the process of determining a valid price forecast for Idexx Laboratories Inc with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Idexx Laboratories Inc ranked in the 14th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. As for the metrics that stood out in our discounted cash flow analysis of Idexx Laboratories Inc, consider:
The company's debt burden, as measured by earnings divided by interest payments, is 18.74 -- which is good for besting 83.48% of its peer stocks (US stocks in the Healthcare sector with positive cash flow).
The business' balance sheet suggests that 3% of the company's capital is sourced from debt; this is greater than only 10.47% of the free cash flow producing stocks we're observing.
IDXX's estimated cost of debt, based largely on its market capitalization and its interest coverage ratio, is 2%; for context, that number is higher than 47.73% of tickers in our DCF set.
Terminal Growth Rate in Free Cash Flow
Return Relative to Current Share Price
For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as IDXX, try MYGN, QGEN, NUVA, EW, and TECH.
According to the new market research report "Veterinary Imaging Market by Product (Ultrasound (2D, Doppler, 3D), X-ray (CR, DR), MRI, CT, Software, Reagent), Therapeutic Area (Oncology, Gynecology, Orthopedic), Animal (Small Companion, Large), End User (Hospital, Clinic) - Global Forecast to
WESTBROOK, Maine, Aug. 10, 2020 /PRNewswire/ -- IDEXX Laboratories, Inc. (NASDAQ: IDXX), a global leader in veterinary diagnostics, veterinary practice software and water microbiology testing, will host its 2020 virtual Investor Day on Thursday, August 13, 2020 from 10:00 am – 12:00 pm ET….